Cost-of-illness studies - A review of current methods

被引:195
作者
Akobundu, Ebere [1 ]
Ju, Jing [1 ]
Blatt, Lisa [1 ]
Mullins, C. Daniel [1 ]
机构
[1] Univ Maryland, Sch Pharm, Pharmaceut Hlth Serv Res Dept, Baltimore, MD 21201 USA
关键词
D O I
10.2165/00019053-200624090-00005
中图分类号
F [经济];
学科分类号
02 ;
摘要
The number of cost-of-illness (COI) studies has expanded considerably over time. One outcome of this growth is that the reported COI estimates are inconsistent across studies, thereby raising concerns over the validity of the estimates and methods. Several factors have been identified in the literature as reasons for the observed variation in COI estimates. To date, the variation in the methods used to calculate costs has not been examined in great detail even though the variations in methods are a major driver of variation in COI estimates. The objective of this review was to document the variation in the methodologies employed in COI studies and to highlight the benefits and limitations of these methods. The review of COI studies was implemented following a four-step procedure: (i) a structured literature search of MEDLINE, JSTOR and EconLit; (ii) a review of abstracts using pre-defined inclusion and exclusion criteria; (iii) a full-text review using pre-defined inclusion and exclusion criteria; and (iv) classification of articles according to the methods used to calculate costs. This review identified four COI estimation methods (Sum All Medical, Sum Diagnosis Specific, Matched Control and Regression) that were used in categorising articles. Also, six components of direct medical costs and five components of indirect/non-medical costs were identified and used in categorising articles. 365 full-length articles were reflected in the current review following the structured literature search. The top five cost components were emergency room/inpatient hospital costs, outpatient physician costs, drug costs, productivity losses and laboratory costs. The dominant method, Sum Diagnosis Specific, was a total costing approach that restricted the summation of medical expenditures to those related to a diagnosis of the disease of interest. There was considerable variation in the methods used within disease subcategories. In several disease subcategories (e.g. asthma, dementia, diabetes mellitus), all four estimation methods were represented, and in other cases (e.g. HIV/AIDS, obesity, stroke, urinary incontinence, schizophrenia), three of the four estimation methods were represented. There was also evidence to suggest that the strengths and weaknesses of each method were considered when applying a method to a specific illness. Comparisons and assessments of COI estimates should consider the method used to estimate costs both as an important source of variation in the reported COI estimates and as a marker of the reliability of the COI estimate.
引用
收藏
页码:869 / 890
页数:22
相关论文
共 392 条
  • [101] Health and disability costs of depressive illness in a major US corporation
    Druss, BG
    Rosenheck, RA
    Sledge, WH
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (08) : 1274 - 1278
  • [102] Comparing the national economic burden of five chronic conditions
    Druss, BG
    Marcus, SC
    Olfson, M
    Tanielian, T
    Elinson, L
    Pincus, HA
    [J]. HEALTH AFFAIRS, 2001, 20 (06) : 233 - 241
  • [103] The economic impact of migraine: An analysis of direct and indirect costs
    Edmeads, J
    Mackell, JA
    [J]. HEADACHE, 2002, 42 (06): : 501 - 509
  • [104] Cost of illness in adult patients with hypopituitarism
    Ehrnborg, C
    Hakkaart-Van Roijen, L
    Jonsson, B
    Rutten, FFH
    Bengtsson, BÅ
    Rosén, T
    [J]. PHARMACOECONOMICS, 2000, 17 (06) : 621 - 628
  • [105] The economic cost of low back pain in Sweden in 2001
    Ekman, M
    Johnell, O
    Lidgren, L
    [J]. ACTA ORTHOPAEDICA, 2005, 76 (02) : 275 - 284
  • [106] Cost of atopic dermatitis and eczema in the United States
    Ellis, CN
    Drake, LA
    Prendergast, MM
    Abramovits, W
    Boguniewicz, M
    Daniel, CR
    Lebwohl, M
    Stevens, SR
    Whitaker-Worth, DL
    Cheng, JW
    Tong, KB
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (03) : 361 - 370
  • [107] Outcomes and cost of deep venous thrombosis among patients with cancer
    Elting, LS
    Escalante, CP
    Cooksley, C
    Avritscher, EBC
    Kurtin, D
    Hamblin, L
    Khosla, G
    Rivera, E
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (15) : 1653 - 1661
  • [108] Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors
    Elting, LS
    Cantor, SB
    Martin, CG
    Hamblin, L
    Kurtin, D
    Rivera, E
    Vadhan-Raj, S
    Benjamin, RS
    [J]. CANCER, 2003, 97 (06) : 1541 - 1550
  • [109] What is the cost of atopic dermatitis in preschool children?
    Emerson, RM
    Williams, HC
    Allen, BR
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (03) : 514 - 522
  • [110] Estimating the costs attributable to a disease with application to ovarian cancer
    Etzioni, R
    Urban, N
    Baker, M
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (01) : 95 - 103